Robert J. Cardnell

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren A. Byers, Lixia Diao, Jing Wang et al. · Clinical Cancer Research · 2012 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

Carl M. Gay, C. Allison Stewart, Elizabeth M. Park et al. · Cancer Cell · 2021 · 932 citations · Full text

Medicine, Cancer Biology, Molecular Biology +10

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

C. Allison Stewart, Pan Tong, Robert J. Cardnell et al. · Oncotarget · 2017 · 227 citations · Full text

Medicine, Oncology, Pharmacology +17

Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC

Triparna Sen, Carminia Maria Della Corte, Snezana Milutinovic et al. · Journal of Thoracic Oncology · 2019 · 119 citations · Full text

Medicine, Oncology, Pharmacology +17

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies

Robert J. Cardnell, Lerong Li, Triparna Sen et al. · Oncotarget · 2017 · 93 citations · Full text

Medicine, Molecular Biology, Oncology +17